Erasmus MC is one of the leading academic hospitals in cancer research in the Netherlands. Its motto is to continue to identify the most promising scientific challenges and bring them to reality, thus personalized cancer vaccines could not go unnoticed by this team of healthcare professionals and researchers. Initiated by Professor van Eijck and Mr. Snijders, FRA GenVax is a powerful blend of the high-level expertise of Erasmus MC and the infrastructure and vision of the Franklin Biotech Research Foundation.
“In the spring of 2020, I was diagnosed with locally advanced pancreatic carcinoma with the encouraging news that it was going to be quite a fight.
After a second and a third opinion that both confirmed my lethal prognosis, I came into the hands of Prof CHJ van Eijck, but not after first completing an 8 x Folfirinox course. Mentioned Folfirinox, which almost everyone is condemned to with such a disease, has mainly been the reason to think about alternative treatments as the chemotherapy not only proves destructive to the tumor but affects your entire functioning. People with pancreatic/pancreatic cancer live on average about 10 weeks after diagnosis...
It is thanks to Prof Van Eijck and thanks to a personalized vaccine that I am still here after 2.5 years. Unfortunately, such a vaccine is not available to everyone. My wish is to change this with FRA GenVax, younger brother of Franklin Biotech Research Foundation, and thereby also boost Prof Van Eijck's and colleagues’ work trajectory.”
- Frank Snijders, August 2022